ASP 8825 [gabapentin enacarbil, XP 13512] phase II study—A double-blind, placebo-controlled study in patients with painful diabetic polyneuropathy

Trial Profile

ASP 8825 [gabapentin enacarbil, XP 13512] phase II study—A double-blind, placebo-controlled study in patients with painful diabetic polyneuropathy

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Nov 2008

At a glance

  • Drugs Gabapentin enacarbil (Primary)
  • Indications Neuropathic pain
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 30 Nov 2008 Nov 2008 added as the actual completion date, based on information from ClinicalTrials.gov.
    • 30 Nov 2008 Status changed from suspended to discontinued, based on information from ClinicalTrials.gov. An independent DMC concluded that continuation was unlikely to demonstrate a statistically significant advantage of ASP8825 over placebo for the primary endpoint.
    • 12 Nov 2008 Status changed from recruiting to suspended, as reported by ClinicalTrials.gov. This trial has been suspended as an interim analysis is being conducted.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top